Kimotar® inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor. Kimotar® expressed on the cell surface of healthy cells and cancer cells, and prevents autophosphorylation of tyrosine residues associated with the receptor, thereby inhibiting further downstream signaling.
It is used for themanagement of locally advanced or metastatic non-small cell lung cancer either in disease that is unresponsive to other therapy, or as maintenance monotherapy in those with stable disease after platinum-based first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.